Bio-Reference Laboratories, Inc. (Numbers in Thousands Except Per Share Data or where otherwise noted) released its second quarter, fiscal year 2010 earnings today for the three months ending April 30. The Company recorded current quarter revenues of $110,447, the best ever quarter in corporate history and an increase of 27% over the $87,183 recorded in the second quarter, fiscal year 2009.

Although congenital heart disease represents the most common major birth defect, scientists have not previously identified the common variation in the genes that give rise to it. Now genetics and cardiology researchers, two of them brothers, have discovered a genetic variant on chromosome 5 that strongly raises the risk of congenital heart disease.

NewLink Genetics Corporation today announced that preliminary data from its Phase 2 clinical trial evaluating the effect of HyperAcute?®-Pancreas immunotherapy in patients with resected pancreatic cancer will be presented during a poster session at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting held June 4-8, 2010 in Chicago, Illinois. A summary of the company's ASCO presentation is below.

A commonly used probe for Positron Emission Tomography scanning and a new probe developed by researchers at UCLA reveal different functions in diverse cells of the immune system, providing a non-invasive and much clearer picture of an immune response in action.

A natural defence mechanism against heart disease could be switched on by steroids sold as health supplements, according to researchers at the University of Leeds.